|

|

|




See Related:
Authors' Articles

Return to
Table of Contents

Author/Article
Information




Author/Article
Information


|

|

|

|

|

Drug-Related Deaths
in a Department of Internal Medicine
Just
Ebbesen, MD; Ingebjørg Buajordet, MSc; Jan Erikssen, MD, PhD; Odd Brørs, MD,
PhD; Thor Hilberg, MD, PhD; Helge Svaar, MD; Leiv Sandvik, MSc, PhD
Background Drug therapy is associated with
adverse effects, and fatal adverse drug events (ADEs) have become major
hospital problems. Our study assesses the incidence of fatal ADEs in a major
medical department and identifies possible patient characteristics signifying
fatal ADE risk.
Methods During a 2-year period, a
multidisciplinary study group examined all 732 patients who died 5.2%
of the 13 992 patients admitted to the Department of Internal Medicine,
Central Hospital of Akershus, Nordbyhagen, Norway. Decisions about the presence
or absence of fatal ADEs were based on aggregated clinical records, autopsy
results, and findings from premortem and postmortem drug analyses.
Results In 18.2% of the patients (133/732)
(95% confidence interval, 15.4%-21.0%), deaths were classified as being
directly (64 [48.1%] of 133) or indirectly (69 [51.9%] of 133) associated
with 1 or more drugs (this equals 9.5 deaths per 1000 hospitalized patients).
Those with fatal ADEs (cases) were older, had more diseases, and used more
drugs than those without fatal ADEs (noncases). In 75 of the 133 patients
with fatal ADEs, autopsy findings and/or drug analysis data were decisive for
recognizing the ADEs; in 62 of the remaining 595 patients, similar data
proved necessary to exclude the suspicion of a fatal ADE. Major culprit drugs
were cardiovascular, antithrombotic, and sympathomimetic agents.
Conclusions Fatal ADEs represent a major
hospital problem, especially in elderly patients with multiple diseases. A
higher number of drugs administered was associated with a higher frequency of
fatal ADEs, but whether a high number of drugs is an independent risk factor
for fatal ADEs is unsettled. Autopsy results and the findings of premortem
and postmortem drug analyses were important for recognizing and excluding suspected
fatal ADEs.
Arch Intern Med.
2001;161:2317-2323
View
Full Text
Author/Article
Information

From the Foundation for Health Services Research (Drs Ebbesen and Sandvik)
and the Departments of Internal Medicine (Dr Erikssen) and Pathology (Dr
Svaar), Central Hospital of Akershus, Nordbyhagen, Norway; and the Norwegian
Medicines Control Authority (Ms Buajordet), the Division of Clinical
Pharmacology and Toxicology, Clinical Chemistry Department, Ullevaal
University Hospital (Dr Brørs), and the National Institute of Forensic
Toxicology (Dr Hilberg), Oslo, Norway.
Corresponding author and reprints: Just Ebbesen, MD, Foundation for Health
Services Research, Central Hospital of Akershus, N-1474 Nordbyhagen, Norway
(e-mail: justebbe@online.no).
Accepted for publication
March 13, 2001.
This study was supported
by The Fund for Quality Improvement in Hospitals from the Norwegian Medical
Association, Oslo; by the Norwegian Medicinal Depot ASA, Oslo; and the Fund
for Research and Development from the Central Hospital of Akershus.
We thank all staff at
participating departments (inside and outside of Central Hospital of
Akershus) for their positive attitude and cooperation and our employers for
giving us time to analyze and finish the project.
|

|

|